Text Size

Is There is a Role of Prophylactic Therapy With Tamsulosin Before Extracorporeal Shock Wave Lithotripsy to Avoid Development of Steinstrasse ?

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2007 by HaEmek Medical Center, Israel.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT00489723
First received: June 19, 2007
Last updated: June 20, 2007
Last verified: June 2007
History of Changes
  Purpose

The purpose of this study is to determine if there is a role of prophylactic therapy with tamsulosin prior extracorporeal shock wave lithotripsy to avoid development of steinstrasse. 150 persons that will go to Extracorporeal shock wave lithotripsy will randomize to 2 groups.

Group 1 -of 75 persons will recieve tamsulosin 0.4 mg x 1/d 2 days before the lithotripsy .

Group 2 - of 75 persons will not recieve tamsulosin. 48 hour after the ESWL all 2 group will take abdominal radiograph to evaluate the presence of steinstrasse.


Condition Intervention
Kidney Stones
 Drug: tamsulosin 0.4mg

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective

Resource links provided by NLM:

MedlinePlus related topics: Kidney Stones Shock
U.S. FDA Resources

Further study details as provided by HaEmek Medical Center, Israel:

Study Start Date: May 2007
  Eligibility

Ages Eligible for Study:   15 Years to 85 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • size of stone 1-2 cm

Exclusion Criteria:

  • ureteral stricture Presence of internal stent prior use of alfa bloker prior ESWL
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00489723

Contacts
Contact: DORON PEREZ, M.D. +972-4-6495115 perez_do@clalit.org.il

Locations
Israel
Haemek medical center Recruiting
Afula, Israel, 18100
Contact: DORON PEREZ, M.D.     +972-4-6495115     perez_do@clalit.org.il    
Principal Investigator: doron perez, M.D.            
Sponsors and Collaborators
HaEmek Medical Center, Israel
Investigators
Principal Investigator: doron perez Urology department: Haemek Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00489723     History of Changes
Other Study ID Numbers: 0056-07-EMC
Study First Received: June 19, 2007
Last Updated: June 20, 2007
Health Authority: Israel: Ethics Commission

Keywords provided by HaEmek Medical Center, Israel:
size of stone 1-2 cm
Pt. with no use of alfa bloker prior ESWL
Pt. without internal stent

Additional relevant MeSH terms:
Kidney Calculi
Nephrolithiasis
Kidney Diseases
Urologic Diseases
Urolithiasis
Urinary Calculi
Calculi
Pathological Conditions, Anatomical
Tamsulosin
 Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 17, 2013